NewsRelease
BiomarkerBook Cites Cleanascite™ To Study Body Fluids
MONMOUTHJUNCTION, NJ,March29, 2019 -- Biotech Support Group reports on a recent book chapterdescribing the simplicity and efficiency of their lipid clearancesample preparation technology for reducing analytical variables inthe proteomic comparison of body fluids.The citation is:
Farina,Annarita. "Pre-fractionationof Noncirculating Biological Fluids to Improve Discovery ofClinically Relevant Protein Biomarkers."Proteomicsfor Biomarker Discovery.Humana Press, New York, NY, 2019. 23-37.
Forproteomic biomarker discovery, it is necessary to bridge the gapbetween basic and applied research by complying with clinicalrequirements.This chapter provides key suggestions for improving the discovery ofclinically relevant protein biomarkers from body fluids. The chapterstates : ”If the elimination of lipids…is necessary, the samplecan by treated with lipid removal (Cleanascite)…
“Iam pleased that Cleanascite™ is cited as a general delipidationreagent for all the different body fluids that can be compared withina proteomic analysis for the discovery of new biomarkers.” statesSwapan Roy, Ph.D., President and Founder of Biotech Support Group.
Formore information visit: Cleanascite™Lipid Removal Reagent and Clarification,at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, gotohttp://www.biotechsupportgroup.com.
Contact:
MatthewKuruc
732-274-2866,[email protected]